Mar 5, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating with a Price Target of $14.00 from CB Capital Partners

Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 19, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12 Month Price Target of $16.00 from D. Boral Capital

Sep 27, 2024

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Aug 14, 2024

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 1, 2024

Estrella Immunopharma Doses First Patient in Phase I/II Trial of EB103 in Advanced B-cell Non-Hodgkin’s Lymphomas

Jan 30, 2024

Estrella Immunopharma Announces $1 Million Share Repurchase Authorization

Jan 24, 2024

Estrella Immunopharma Announces Publication in Blood Demonstrating ARTEMIS T Cell’s Potential in Addressing Acute Myeloid Leukemia (AML)

Sep 29, 2023

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Mar 8, 2023

Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas

Nov 14, 2022

Imugene’s onCARlytics combination with Estrella’s CD19-Redirected ARTEMIS® T Cells presented at SITC Annual Meeting

Oct 3, 2022

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.